EANM enabling guide: how to improve the accessibility of clinical dosimetry

doi:10.1007/s00259-023-06226-z

. 2023 Jun;50(7):1861-1868.

doi: 10.1007/s00259-023-06226-z. Epub 2023 Apr 22.

EANM enabling guide: how to improve the accessibility of clinical dosimetry

Jonathan Gear¹, Caroline Stokke^{2

3}, Christelle Terwinghe⁴, Silvano Gnesin⁵, Mattias Sandström^{6

7}, Johannes Tran-Gia⁸, Marta Cremonesi⁹, Francesco Cicone^{10

11}, Fredrik Verburg¹², Roland Hustinx^{13

14}, Luca Giovanella¹⁵, Ken Herrmann^{16

17}, Pablo Minguez Gabiña^{18

19}

Affiliations

¹ Joint Department of Physics, Royal Marsden NHSFT & Institute of Cancer Research, Sutton, UK. jonathan.gear@icr.ac.uk.
² Division of Radiology and Nuclear Medicine, Oslo University Hospital, Oslo, Norway.
³ Department of Physics, University of Oslo, Oslo, Norway.
⁴ Department of Nuclear Medicine, Universitair Ziekenhuis Leuven, Louvain, Belgium.
⁵ Institute of Radiation Physics, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland.
⁶ Section of Nuclear Medicine and PET, Department of Surgical Sciences, Uppsala University, Uppsala, Sweden.
⁷ Sweden & Section of Medical Physics, Department of Immunology, Genetics and Pathology, Uppsala University, 751 85, Uppsala, Sweden.
⁸ Department of Nuclear Medicine, University Hospital Würzburg, Oberdürrbacher Str. 6, 97080, Würzburg, Germany.
⁹ Radiation Research Unit, Department of Medical Imaging and Radiation Sciences, Istituto Europeo Di Oncologia, IRCCS, Milan, Italy.
¹⁰ Department of Experimental and Clinical Medicine, Neuroscience Research Centre, PET/RM Unit, "Magna Graecia" University of Catanzaro, Catanzaro, Italy.
¹¹ Nuclear Medicine Unit, University Hospital "Mater Domini, Catanzaro, Italy.
¹² Department of Radiology and Nuclear Medicine, Erasmus Medical Center, Rotterdam, the Netherlands.
¹³ Division of Nuclear Medicine and Oncological Imaging, University Hospital of Liège, Liège, Belgium.
¹⁴ GIGA-CRC in Vivo Imaging, University of Liège, Liège, Belgium.
¹⁵ Clinic for Nuclear Medicine and Molecular Imaging, Imaging Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland.
¹⁶ Department of Nuclear Medicine, University of Duisburg-Essen, Duisburg, Germany.
¹⁷ German Cancer Consortium (DKTK)-University Hospital Essen, Essen, Germany.
¹⁸ Department of Medical Physics and Radiation Protection, Gurutzeta-Cruces University Hospital/Biocruces Health Research Institute, Barakaldo, Spain.
¹⁹ Department of Applied Physics, Faculty of Engineering, UPV/EHU, Bilbao, Spain.

PMID: 37086275
PMCID: PMC10287783
DOI: 10.1007/s00259-023-06226-z

EANM enabling guide: how to improve the accessibility of clinical dosimetry

Jonathan Gear et al. Eur J Nucl Med Mol Imaging. 2023 Jun.

. 2023 Jun;50(7):1861-1868.

doi: 10.1007/s00259-023-06226-z. Epub 2023 Apr 22.

Authors

Affiliations

¹ Joint Department of Physics, Royal Marsden NHSFT & Institute of Cancer Research, Sutton, UK. jonathan.gear@icr.ac.uk.
² Division of Radiology and Nuclear Medicine, Oslo University Hospital, Oslo, Norway.
³ Department of Physics, University of Oslo, Oslo, Norway.
⁴ Department of Nuclear Medicine, Universitair Ziekenhuis Leuven, Louvain, Belgium.
⁵ Institute of Radiation Physics, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland.
⁶ Section of Nuclear Medicine and PET, Department of Surgical Sciences, Uppsala University, Uppsala, Sweden.
⁷ Sweden & Section of Medical Physics, Department of Immunology, Genetics and Pathology, Uppsala University, 751 85, Uppsala, Sweden.
⁸ Department of Nuclear Medicine, University Hospital Würzburg, Oberdürrbacher Str. 6, 97080, Würzburg, Germany.
⁹ Radiation Research Unit, Department of Medical Imaging and Radiation Sciences, Istituto Europeo Di Oncologia, IRCCS, Milan, Italy.
¹⁰ Department of Experimental and Clinical Medicine, Neuroscience Research Centre, PET/RM Unit, "Magna Graecia" University of Catanzaro, Catanzaro, Italy.
¹¹ Nuclear Medicine Unit, University Hospital "Mater Domini, Catanzaro, Italy.
¹² Department of Radiology and Nuclear Medicine, Erasmus Medical Center, Rotterdam, the Netherlands.
¹³ Division of Nuclear Medicine and Oncological Imaging, University Hospital of Liège, Liège, Belgium.
¹⁴ GIGA-CRC in Vivo Imaging, University of Liège, Liège, Belgium.
¹⁵ Clinic for Nuclear Medicine and Molecular Imaging, Imaging Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland.
¹⁶ Department of Nuclear Medicine, University of Duisburg-Essen, Duisburg, Germany.
¹⁷ German Cancer Consortium (DKTK)-University Hospital Essen, Essen, Germany.
¹⁸ Department of Medical Physics and Radiation Protection, Gurutzeta-Cruces University Hospital/Biocruces Health Research Institute, Barakaldo, Spain.
¹⁹ Department of Applied Physics, Faculty of Engineering, UPV/EHU, Bilbao, Spain.

PMID: 37086275
PMCID: PMC10287783
DOI: 10.1007/s00259-023-06226-z

Erratum in

Correction to: EANM enabling guide: how to improve the accessibility of clinical dosimetry.
Gear J, Stokke C, Terwinghe C, Gnesin S, Sandström M, Tran-Gia J, Cremonesi M, Cicone F, Verburg F, Hustinx R, Giovanella L, Herrmann K, Gabiña PM. Gear J, et al. Eur J Nucl Med Mol Imaging. 2023 Aug;50(10):3157-3158. doi: 10.1007/s00259-023-06304-2. Eur J Nucl Med Mol Imaging. 2023. PMID: 37382664 Free PMC article. No abstract available.

Abstract

Dosimetry can be a useful tool for personalization of molecular radiotherapy (MRT) procedures, enabling the continuous development of theranostic concepts. However, the additional resource requirements are often seen as a barrier to implementation. This guide discusses the requirements for dosimetry and demonstrates how a dosimetry regimen can be tailored to the available facilities of a centre. The aim is to help centres wishing to initiate a dosimetry service but may not have the experience or resources of some of the more established therapy and dosimetry centres. The multidisciplinary approach and different personnel requirements are discussed and key equipment reviewed example protocols demonstrating these factors are given in the supplementary material for the main therapies carried out in nuclear medicine, including [¹³¹I]-NaI for benign thyroid disorders, [¹⁷⁷Lu]-DOTATATE and ¹³¹I-mIBG for neuroendocrine tumours and [⁹⁰Y]-microspheres for unresectable hepatic carcinoma.

Keywords: Dosimetry; Molecular radiotherapy; Nuclear medicine; Optimisation; Quantitative imaging; SPECT.

PubMed Disclaimer

Conflict of interest statement

KH reports personal fees from Bayer, personal fees and other from Sofie Biosciences, personal fees from SIRTEX, non-financial support from ABX, personal fees from Adacap, personal fees from Curium, personal fees from Endocyte, grants and personal fees from BTG, personal fees from IPSEN, personal fees from Siemens Healthineers, personal fees from GE Healthcare, personal fees from Amgen, personal fees from Novartis, personal fees from ymabs, all outside the submitted work. LG reports personal fees from Roche Diagnostics and SNIBE for advisory board participation, and research support from Roche Diagnostics., all outside the submitted work.

Cited by

Patients, parents and professional perspectives on molecular radiotherapy for neuroblastoma and paediatric neuroendocrine cancers.
Whittaker L, Knox L, Aitchison Z, Peet C, O'Donovan A, Gray J, Wan S, Flux GD, Gaze MN. Whittaker L, et al. Nucl Med Commun. 2025 Apr 1;46(4):373-377. doi: 10.1097/MNM.0000000000001956. Epub 2025 Jan 23. Nucl Med Commun. 2025. PMID: 39844505 Free PMC article.
EANM perspectives for CZT SPECT in brain applications.
Verger A, Cecchin D, Guedj E, Albert NL, Brendel M, Fraioli F, Tolboom N, Traub-Weidinger T, Yakushev I, Van Weehaeghe D, Fernandez PA, Garibotto V, Imbert L. Verger A, et al. Eur J Nucl Med Mol Imaging. 2024 Oct;51(12):3680-3684. doi: 10.1007/s00259-024-06788-6. Eur J Nucl Med Mol Imaging. 2024. PMID: 38858281 No abstract available.
Do we need dosimetry for the optimization of theranostics in CNS tumors?
Cicone F, Gnesin S, Santo G, Stokke C, Bartolomei M, Cascini GL, Minniti G, Paganelli G, Verger A, Cremonesi M. Cicone F, et al. Neuro Oncol. 2024 Dec 9;26(Supplement_9):S242-S258. doi: 10.1093/neuonc/noae200. Neuro Oncol. 2024. PMID: 39351795 Review.
EANM expert opinion: How can lessons from radiobiology be applied to the design of clinical trials? Part I: back to the basics of absorbed dose-response and threshold absorbed doses.
Pouget JP, Gabina PM, Herrmann K, Deandreis D, Konijnenberg M, Taieb D, van Leeuwen FWB, Kurth J, Eberlein U, Lassmann M, Lückerath K; EANM Radiobiology Working Group. Pouget JP, et al. Eur J Nucl Med Mol Imaging. 2025 Feb;52(3):1210-1222. doi: 10.1007/s00259-024-06963-9. Epub 2024 Nov 12. Eur J Nucl Med Mol Imaging. 2025. PMID: 39531084 Free PMC article. Review.
A review of 177Lu dosimetry workflows: how to reduce the imaging workloads?
Vergnaud L, Dewaraja YK, Giraudet AL, Badel JN, Sarrut D. Vergnaud L, et al. EJNMMI Phys. 2024 Jul 18;11(1):65. doi: 10.1186/s40658-024-00658-8. EJNMMI Phys. 2024. PMID: 39023648 Free PMC article. Review.

References

1. Chiesa C, et al. A dosimetric treatment planning strategy in radioembolization of hepatocarcinoma with Y-90 glass microspheres. Q J Nucl Med Mol Imaging. 2012;56(6):503–508. - PubMed
1. Del Prete M, Buteau FA, Beauregard JM. Personalized Lu-177-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: a simulation study. Eur J Nucl Med Mol Imaging. 2017;44(9):1490–1500. doi: 10.1007/s00259-017-3688-2. - DOI - PubMed
1. Maxon HR, et al. Radioiodine-131 therapy for well-differentiated thyroid-cancer - a quantitative radiation dosimetric approach - outcome and validation in 85 patients. J Nucl Med. 1992;33(6):1132–1136. - PubMed
1. Sandstrom M, et al. Individualized dosimetry of kidney and bone marrow in patients undergoing Lu-177-DOTA-octreotate treatment. J Nucl Med. 2013;54(1):33–41. doi: 10.2967/jnumed.112.107524. - DOI - PubMed
1. Stokkel MPM, et al. EANM procedure guidelines for therapy of benign thyroid disease. Eur J Nucl Med Mol Imaging. 2010;37(11):2218–2228. doi: 10.1007/s00259-010-1536-8. - DOI - PubMed

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
Miscellaneous
- NCI CPTAC Assay Portal

[1] Chiesa C, et al. A dosimetric treatment planning strategy in radioembolization of hepatocarcinoma with Y-90 glass microspheres. Q J Nucl Med Mol Imaging. 2012;56(6):503–508. - PubMed

[2] Chiesa C, et al. A dosimetric treatment planning strategy in radioembolization of hepatocarcinoma with Y-90 glass microspheres. Q J Nucl Med Mol Imaging. 2012;56(6):503–508. - PubMed

[3] Del Prete M, Buteau FA, Beauregard JM. Personalized Lu-177-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: a simulation study. Eur J Nucl Med Mol Imaging. 2017;44(9):1490–1500. doi: 10.1007/s00259-017-3688-2. - DOI - PubMed

[4] Del Prete M, Buteau FA, Beauregard JM. Personalized Lu-177-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: a simulation study. Eur J Nucl Med Mol Imaging. 2017;44(9):1490–1500. doi: 10.1007/s00259-017-3688-2. - DOI - PubMed

[5] Maxon HR, et al. Radioiodine-131 therapy for well-differentiated thyroid-cancer - a quantitative radiation dosimetric approach - outcome and validation in 85 patients. J Nucl Med. 1992;33(6):1132–1136. - PubMed

[6] Maxon HR, et al. Radioiodine-131 therapy for well-differentiated thyroid-cancer - a quantitative radiation dosimetric approach - outcome and validation in 85 patients. J Nucl Med. 1992;33(6):1132–1136. - PubMed

[7] Sandstrom M, et al. Individualized dosimetry of kidney and bone marrow in patients undergoing Lu-177-DOTA-octreotate treatment. J Nucl Med. 2013;54(1):33–41. doi: 10.2967/jnumed.112.107524. - DOI - PubMed

[8] Sandstrom M, et al. Individualized dosimetry of kidney and bone marrow in patients undergoing Lu-177-DOTA-octreotate treatment. J Nucl Med. 2013;54(1):33–41. doi: 10.2967/jnumed.112.107524. - DOI - PubMed

[9] Stokkel MPM, et al. EANM procedure guidelines for therapy of benign thyroid disease. Eur J Nucl Med Mol Imaging. 2010;37(11):2218–2228. doi: 10.1007/s00259-010-1536-8. - DOI - PubMed

[10] Stokkel MPM, et al. EANM procedure guidelines for therapy of benign thyroid disease. Eur J Nucl Med Mol Imaging. 2010;37(11):2218–2228. doi: 10.1007/s00259-010-1536-8. - DOI - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

EANM enabling guide: how to improve the accessibility of clinical dosimetry

Affiliations

EANM enabling guide: how to improve the accessibility of clinical dosimetry

Authors

Affiliations

Erratum in

Abstract

Conflict of interest statement

Similar articles

Cited by

References

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Miscellaneous

Erratum in

Abstract

Conflict of interest statement

Similar articles

Cited by

References

MeSH terms

Substances

Related information

LinkOut - more resources

Full Text Sources

Miscellaneous